The Patent Finder

Terms ending in 2029

CSL Behring GmbH

Every in-force patent on CSL Behring GmbH's record whose computed term ends in 2029, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 8,394,768Synergistic Therapeutic Use of Prothrombin Complex Concentrates with Fviii Concentrates
In force
 · High confidence
CSL Behring GmbHIn forceHigh confidence
US 9,095,564Von Willebrand Factor or Factor VIII and Von Willebrand Factor for the Treatment of Coagulopathy Induced by Inhibitors of Thrombocytes
In force
 · High confidence
CSL Behring GMBHIn forceHigh confidence
US 10,137,165Factor H for the Treatment of Chronic Nephropathies and Production Thereof
In force
 · High confidence
CSL Behring GmbHIn forceHigh confidence
3 of 3 patents shown. Soonest term end first, then patent number.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited